ScreenerHero

OCGNOcugen, Inc.

NAS · US · Healthcare · Biotechnology · ocugen.com
1.390USD-6.08%Mkt Cap: 471.36M $P/E: —

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product inclu…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap471.36M $
Enterprise Value459.30M $
Revenue (TTM)4.58M $
Gross Profit-39.18M $
Net Income (TTM)-67.85M $
Revenue/Share0.0140 USD
Last Price1.390 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees116
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.21
PEG—
EV/EBITDA-6.84
EV/Revenue100.26
P/S102.90
P/B-28.37
EPS (TTM)-0.24
EPS (Forward)-0.27
52W Range
0.980023% of range2.725
52W High2.725 USD
52W Low0.9800 USD
Profitability
Gross Margin0.00%
Oper. Margin-1105.11%
EBITDA Margin0.00%
Profit Margin-1537.41%
ROE557.67%
ROA-155.91%
Growth
Revenue Growth8.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-56.96M $
CapEx (TTM)185.00K $
FCF Margin-43.10%
FCF Yield-0.42%
Net Debt-12.06M $
Net Debt/EBITDA0.18
Balance Sheet
Debt/Equity-2.72
Current Ratio0.80
Quick Ratio0.75
Book Value/Sh-0.0490 USD
Cash/Share0.2950 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateSep 30, 2019
Splits
Last Split1:60
Split DateSep 30, 2019
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.17 USD
Upside (mean)+775.3%
Target Range8.000 USD – 22.00 USD
$8.000+775.3% to mean$22.00
# Analysts6
Ownership
Shares Out.339.11M
Float333.39M
Insiders1.68%
Institutions43.29%
Short Interest
Short Ratio19.1d
Short % Float29.92%
Short % Out.29.76%
Shares Short100.91M
Short (prev mo.)105.43M
Technical
SMA 501.347 (+3.2%)
SMA 2001.509 (-7.9%)
Beta2.20
S&P 52W Chg18.16%
Avg Vol (30d)4.41M
Avg Vol (10d)3.68M
Technical Indicators
RSI (14)54.0
MACD0.0152
MACD Signal-0.0047
MACD Hist.+0.0199
BB Upper1.452 USD
BB Middle1.302 USD
BB Lower1.153 USD
BB Width22.92%
ATR (14)0.0801 USD
Vol Ratio (20d)0.55x